Compare JUBILANT LIFE SCIENCES with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs BIOCON - Comparison Results

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES BIOCON JUBILANT LIFE SCIENCES/
BIOCON
 
P/E (TTM) x 14.3 19.4 73.8% View Chart
P/BV x 1.7 3.0 55.7% View Chart
Dividend Yield % 0.9 0.4 231.1%  

Financials

 JUBILANT LIFE SCIENCES   BIOCON
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-19
BIOCON
Mar-18
JUBILANT LIFE SCIENCES/
BIOCON
5-Yr Chart
Click to enlarge
High Rs8981,188 75.6%   
Low Rs618305 202.5%   
Sales per share (Unadj.) Rs572.068.7 832.3%  
Earnings per share (Unadj.) Rs36.27.6 479.7%  
Cash flow per share (Unadj.) Rs59.514.0 426.0%  
Dividends per share (Unadj.) Rs4.501.00 450.0%  
Dividend yield (eoy) %0.60.1 443.3%  
Book value per share (Unadj.) Rs301.986.3 349.7%  
Shares outstanding (eoy) m159.28600.00 26.5%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x1.310.9 12.2%   
Avg P/E ratio x20.998.9 21.2%  
P/CF ratio (eoy) x12.753.4 23.8%  
Price / Book Value ratio x2.58.6 29.0%  
Dividend payout %12.413.2 93.8%   
Avg Mkt Cap Rs m120,694447,900 26.9%   
No. of employees `0002.46.1 38.9%   
Total wages/salary Rs m19,2609,311 206.8%   
Avg. sales/employee Rs Th38,120.66,705.8 568.5%   
Avg. wages/employee Rs Th8,058.41,514.2 532.2%   
Avg. net profit/employee Rs Th2,414.3736.9 327.6%   
INCOME DATA
Net Sales Rs m91,10841,234 221.0%  
Other income Rs m3572,062 17.3%   
Total revenues Rs m91,46643,296 211.3%   
Gross profit Rs m17,3908,291 209.7%  
Depreciation Rs m3,7093,851 96.3%   
Interest Rs m2,198615 357.4%   
Profit before tax Rs m11,8405,887 201.1%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,8020-   
Tax Rs m3,2681,569 208.3%   
Profit after tax Rs m5,7704,531 127.3%  
Gross profit margin %19.120.1 94.9%  
Effective tax rate %27.626.7 103.6%   
Net profit margin %6.311.0 57.6%  
BALANCE SHEET DATA
Current assets Rs m45,84841,486 110.5%   
Current liabilities Rs m20,89721,413 97.6%   
Net working cap to sales %27.448.7 56.3%  
Current ratio x2.21.9 113.2%  
Inventory Days Days5764 88.8%  
Debtors Days Days5194 54.1%  
Net fixed assets Rs m65,49850,661 129.3%   
Share capital Rs m1593,000 5.3%   
"Free" reserves Rs m47,93048,808 98.2%   
Net worth Rs m48,08951,808 92.8%   
Long term debt Rs m42,42917,898 237.1%   
Total assets Rs m114,68599,897 114.8%  
Interest coverage x6.410.6 60.4%   
Debt to equity ratio x0.90.3 255.4%  
Sales to assets ratio x0.80.4 192.5%   
Return on assets %6.95.2 134.9%  
Return on equity %12.08.7 137.2%  
Return on capital %12.49.6 128.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,42212,058 103.0%   
Fx outflow Rs m17,2277,348 234.4%   
Net fx Rs m-4,8054,710 -102.0%   
CASH FLOW
From Operations Rs m11,2156,621 169.4%  
From Investments Rs m-10,118-6,840 147.9%  
From Financial Activity Rs m6,574-2,397 -274.3%  
Net Cashflow Rs m7,612-2,612 -291.4%  

Share Holding

Indian Promoters % 45.6 40.4 112.9%  
Foreign collaborators % 3.5 20.6 17.0%  
Indian inst/Mut Fund % 8.7 8.4 103.6%  
FIIs % 21.2 10.7 198.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 19.9 106.0%  
Shareholders   23,815 109,995 21.7%  
Pledged promoter(s) holding % 15.9 0.0 39,625.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  WOCKHARDT  NOVARTIS  PANACEA BIOTECH  

Compare JUBILANT LIFE SCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Oct 18, 2019 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - DIVIS LABORATORIES COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS